X4 Pharmaceuticals
XFOR
43 hedge funds and large institutions have $114M invested in X4 Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 20 increasing their positions, 1 reducing their positions, and 3 closing their positions.
1,900% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 1
500% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 3
266% more capital invested
Capital invested by funds: $31.1M → $114M (+$82.8M)
48% more funds holding
Funds holding: 29 → 43 (+14)
1.15% more ownership
Funds ownership: 0.89% → 2.04% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$15.2M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$14.6M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$10.8M |
| 4 |
O
OrbiMed
New York
|
+$10.6M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$9.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.19M |
| 2 |
CHP
Cable Hill Partners
Portland,
Oregon
|
-$5K |
| 3 |
Barclays
London,
United Kingdom
|
-$4K |
| 4 |
MAM
Meeder Asset Management
Dublin,
Ohio
|
-$3.05K |
XFOR Hedge Fund Activity: Q2 2019 in Review
43 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q2 2019, worth a combined $114M — up 266% from $31.1M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new XFOR positions and 3 closed out — a net gain of 15 holders — while 20 added to existing stakes and 1 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $15.2M. The largest seller was Federated Hermes, exiting entirely with an estimated $1.19M sold.
- 43 institutional investors held X4 Pharmaceuticals (XFOR) as of Q2 2019, up from 29 in Q1 2019.
- Funds reported $114M of X4 Pharmaceuticals stock for Q2 2019, up 266% quarter-over-quarter.
- 18 funds opened new X4 Pharmaceuticals positions in Q2 2019 and 3 closed out, a net change of +15 holders.
- The largest X4 Pharmaceuticals buyer in Q2 2019 was Fidelity Investments, an estimated $15.2M added.
- The largest X4 Pharmaceuticals seller in Q2 2019 was Federated Hermes, an estimated $1.19M sold.
Based on aggregated 13F filings for Q2 2019.